Press "Enter" to skip to content

Glenmark Pharma says USFDA has issued CRL for Ryaltris

The CRL cites deficiencies in the Drug Master File pertaining to one of the active pharmaceutical ingredients and in manufacturing facilities, the company said in a regulatory filing.

Original source:

Also Read:   Novartis appoints Susanne Schaffert to lead oncology business